Itamar Raz, MD: Impact of Dapagliflozin on Rapid Decline of eGFR

Even before the start of the American Diabetes Association’s (ADA) 80th Scientific Sessions, dapagliflozin was one of, if not, the most discussed agents across all of medicine in 2020. 



Data released as part of the ADA’s annual conference is sure to add greater excitement to that conversation, including analyses examining the incidence of diabetes and impact of background glucose-lowering therapies on heart failure benefit. An additional analysis from the virtual meeting examined the impact of dapagliflozin on risk for fast decline in estimated glomerular filtration rate (eGFR) using data from the DECLARE-TIMI 58 trial. 



Presented by Itamar Raz, MD, head of the Diabetes Unit of Hadassah Hebrew University Hospital in Jerusalem, Israel, results of the post-hoc analysis indicate dapagliflozin was associated with reduced risk for fast decline in eGFR in patients with relatively preserved renal function across all subgroups, regardless of baseline characteristics.

Using the 17,160 patients in the DECLARE-TIMI 58 trial, investigators designed their analysis with the intent of comparing risk for fast decline in eGFR across patients receiving placebo and dapagliflozin. Overall, 26.8% of patients receiving dapagliflozin and 37.1% of patients receiving placebo experienced fast decline in eGFR (P <.0001).

Among patients who experienced a fast decline in eGFR, the mean reduction in eGFR per year was 6.3 (3.7) ml/min/1.73m2/year compared to 0.0 (2.5) ml/min/1.73m2/year in those who did not experience a fast decline in eGFR. During the study period, which lasted from 0.5-4 years, fast decline in eGFR was reduced with use of dapagliflozin (P <.0001).

For more insight into this analysis of the DELCARE-TIMI 58 trial, HCPLive® reached out to Raz to take part in a special edition ADA 2020 HCPLive House Call.

This study, “Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial,” was presented at ADA 2020.